<DOC>
	<DOC>NCT02013141</DOC>
	<brief_summary>This is a multicenter, open-label, single-dose pharmacokinetic (PK) study. Infants, children, and adolescents will receive a single 10 mg/kg dose of telavancin infused intravenously (IV) over 60 minutes</brief_summary>
	<brief_title>Telavancin Pediatric PK Study (Ages &gt;3 Months to 17 Years)</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Telavancin</mesh_term>
	<criteria>Subject is aged &gt;3 months to 17 years (inclusive) and has a weight within the 3rd to 97th percentile (inclusive) for age and sex Subject requires or recently completed systemic antibiotic therapy for the treatment or prevention of a known or suspected bacterial infection Subject has an estimated creatinine clearance &lt;50 mL/min/1.73 m2 (Schwartz equation) Subject has a history of allergies or hypersensitivities to glycopeptide antibiotics (e.g., vancomycin), telavancin, or the formulation excipients Subject has clinically relevant cardiac abnormality, in the opinion of the investigator Subject was treated with an investigational drug within 30 days or five halflives, whichever is longer, before study entry</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Gram positive bacteria</keyword>
	<keyword>Telavancin</keyword>
	<keyword>VIBATIV</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>